Liver Cell Carcinoma
10
2
3
1
Key Insights
Highlights
Success Rate
25% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
30.0%
3 terminated out of 10 trials
25.0%
-61.5% vs benchmark
20%
2 trials in Phase 3/4
300%
3 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (10)
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors
Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors
Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors
Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC
TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma
A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma
HepATocellular Cancer Hcv Therapy Study
Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma